Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Vaxcyte, Inc. (PCVX)

Vaxcyte reports positive OPUS-1 Phase 3 topline data for VAX-31 pneumococcal vaccine

Positive Impact 4 of 5 product/contract Written later

Vaxcyte said its pivotal Phase 3 OPUS-1 adult trial met all prespecified primary endpoints for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, compared with Prevnar 20 and Capvaxive. The company said the results will serve as the cornerstone of a planned Biologics License Application to the FDA, with results from OPUS-2 and OPUS-3 expected in the first half of 2027. The filing contains no revenue, earnings or cash figures, and the data remain subject to FDA review.

Key points

  • All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion in adults 50 and older.
  • VAX-31 met noninferiority for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; serotypes 3 and 12F missed the stricter criterion against PCV21.
  • OPUS-2 and OPUS-3 results are expected in the first half of 2027, and a Biologics License Application submission is planned for the first half of 2028.

The filing

CompanyVaxcyte, Inc. (PCVX)
Form8-K, current report
Filed with the SECOct 5, 2026, 8:01 AM ET
Accession number0001193125-26-413168

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.